MacroGenics reported $20.16M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
AbbVie USD 5.81B 4.36B Dec/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Biogen USD 659.6M 157M Sep/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Genmab DKK 432M 900.27M Jun/2025
Geron USD -13.89M 1.43M Sep/2025
Gilead Sciences USD 2.96B 551M Dec/2025
J&J USD 5.11B 2.3B Dec/2025
Karyopharm Therapeutics USD -26.28M 1.84M Sep/2024
MacroGenics USD 20.16M 55.51M Sep/2025
Merck USD 6.24B 1.32B Dec/2025
Pfizer USD 4.65B 71M Dec/2025
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Xencor USD -47.52M 24.69M Sep/2025